

CYP4Z1 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP7886a**Specification**

CYP4Z1 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [Q86W10](#)**CYP4Z1 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 199974**Other Names**

Cytochrome P450 4Z1, CYP4Z1, CYP4Z1

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7886a](/products/AP7886a) was selected from the N-term region of human CYP4Z1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CYP4Z1 Antibody (N-term) Blocking Peptide - Protein Information**Name** CYP4Z1 {ECO:0000303|PubMed:19090726, ECO:0000312|HGNC:HGNC:20583}**Function**

A cytochrome P450 monooxygenase that catalyzes the in-chain oxidation of fatty acids (PubMed: [19090726](http://www.uniprot.org/citations/19090726), PubMed: [29018033](http://www.uniprot.org/citations/29018033)). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates lauric and myristic acids predominantly at the omega-4 and omega-2 positions, respectively (PubMed: [19090726](http://www.uniprot.org/citations/19090726), PubMed: [29018033](http://www.uniprot.org/citations/29018033)). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). Displays an absolute stereoselectivity in the epoxidation of arachidonic acid producing the 14(S),15(R)-epoxyeicosatrienoic acid (EET) enantiomer (PubMed: [29018033](http://www.uniprot.org/citations/29018033)). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing

the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:19090726, PubMed:29018033).

Cellular Location

Endoplasmic reticulum membrane; Single-pass type II membrane protein. Microsome membrane; Single-pass type II membrane protein

Tissue Location

Preferentially detected in breast carcinoma tissue and mammary gland, whereas only marginal expression is found in all other tested tissues.

CYP4Z1 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CYP4Z1 Antibody (N-term) Blocking Peptide - Images**CYP4Z1 Antibody (N-term) Blocking Peptide - Background**

CYP4Z1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids.

CYP4Z1 Antibody (N-term) Blocking Peptide - References

Savas,U., Arch. Biochem. Biophys. 436 (2), 377-385 (2005)Rieger,M.A., Cancer Res. 64 (7), 2357-2364 (2004)